CD28-mediated co-stimulation: A quantitative support for TCR signalling, Nat. Rev. Immunol, vol.3, pp.939-951, 2003. ,
Trans-endocytosis of CD80 and CD86: A molecular basis for the cell-extrinsic function of CTLA-4, Science, vol.332, pp.600-603, 2011. ,
CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement, Proc. Natl. Acad. Sci, vol.112, pp.524-529, 2015. ,
Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4, Science, vol.272, pp.1170-1173, 1996. ,
DOI : 10.1126/science.272.5265.1170
Cytotoxic T lymphocyte antigen 4 and CD28 modulate cell surface raft expression in their regulation of T cell function, J. Exp. Med, vol.194, pp.1675-1681, 2001. ,
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4, Science, vol.270, pp.985-988, 1995. ,
DOI : 10.1126/science.270.5238.985
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4, Immunity, vol.3, pp.541-547, 1995. ,
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease, Nature, vol.423, pp.506-511, 2003. ,
Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: The possible implications for immunotherapy with CTLA-4 blocking antibody, Tumour Biol, vol.37, pp.4143-4157, 2016. ,
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses, Immunity, vol.27, pp.111-122, 2007. ,
DOI : 10.1016/j.immuni.2007.05.016
URL : https://doi.org/10.1016/j.immuni.2007.05.016
Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation, Sci. Transl. Med, vol.2, 2010. ,
DOI : 10.1126/scitranslmed.3000116
URL : http://europepmc.org/articles/pmc2860737?pdf=render
Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells, PLoS ONE, vol.8, 2013. ,
DOI : 10.1371/journal.pone.0083139
URL : https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0083139&type=printable
CTLA4-Ig restores rejection of MHC class-II mismatched allografts by disabling IL-2-expanded regulatory T cells, Am. J. Transplant, vol.12, pp.2313-2321, 2012. ,
DOI : 10.1111/j.1600-6143.2012.04184.x
URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1600-6143.2012.04184.x/pdf
CD28/CTLA-4/B7 costimulatory pathway blockade affects regulatory T-cell function in autoimmunity, Eur J. Immunol, vol.45, pp.1832-1841, 2015. ,
DOI : 10.1002/eji.201445190
Selective blockade of CD28 on human T cells facilitates regulation of alloimmune responses, JCI Insight, vol.2, p.89381, 2017. ,
Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody, Blood, vol.102, pp.564-570, 2003. ,
A monovalent anti-human CD28 domain antibody antagonist: Preclinical efficacy and safety, J. Immunol, vol.191, pp.4599-4610, 2013. ,
DOI : 10.4049/jimmunol.1300470
URL : http://www.jimmunol.org/content/jimmunol/191/9/4599.full.pdf
Candida-elicited murine Th17 cells express high Ctla-4 compared with Th1 cells and are resistant to costimulation blockade, J. Immunol, vol.192, pp.2495-2504, 2014. ,
DOI : 10.4049/jimmunol.1301332
URL : http://www.jimmunol.org/content/jimmunol/192/5/2495.full.pdf
CD28-specific immunomodulating antibodies: What can be learned from experimental models?, Am. J. Transplant, vol.12, pp.1682-1690, 2012. ,
DOI : 10.1111/j.1600-6143.2012.04032.x
URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1600-6143.2012.04032.x/pdf
Antagonist properties of monoclonal antibodies targeting human CD28: Role of valency and the heavy-chain constant domain. mAbs, vol.5, pp.47-55, 2013. ,
Prolonged allograft survival but no tolerance induction by modulating CD28 antibody JJ319 after high-responder rat heart transplantation, Transplantation, vol.67, pp.392-398, 1999. ,
DOI : 10.1097/00007890-199902150-00009
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412, N. Engl. J. Med, vol.355, pp.1018-1028, 2006. ,
Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists, J. Exp. Med, vol.197, pp.955-966, 2003. ,
A blocking anti-CD28-specific antibody induces long-term heart allograft survival by suppression of the PKC theta-JNK signal pathway, Transplantation, vol.85, pp.1051-1055, 2008. ,
Fc-Silent, Anti-CD28 antibody, improves psoriasis in the SCID mouse-psoriasis xenograft model, J. Investig. Dermatol, vol.128, pp.1969-1976, 2008. ,
Immunomodulatory properties of FK734, a humanized anti-CD28 monoclonal antibody with agonistic and antagonistic activities, Transplantation, vol.83, pp.304-313, 2007. ,
Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody, Am. J. Transplant, vol.12, pp.2630-2640, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-02167934
First-in-Human Study in Healthy Subjects with FR104, a Pegylated Monoclonal Antibody Fragment Antagonist of CD28, J. Immunol, vol.197, pp.4593-4602, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-02150993
Mechanisms regulating skin immunity and inflammation, Nat. Rev. Immunol, vol.14, pp.289-301, 2014. ,
, N. Engl. J. Med, vol.361, pp.496-509, 2009.
Unmet Needs in the Field of Psoriasis: Pathogenesis and Treatment, Clin. Rev. Allergy Immunol, 2017. ,
Psoriasis pathogenesis and the development of novel targeted immune therapies, J. Allergy Clin. Immunol, vol.140, pp.645-653, 2017. ,
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris, J. Clin. Investig, vol.103, pp.1243-1252, 1999. ,
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis, Ann. Rheum. Dis, vol.76, pp.1550-1558, 2017. ,
CTLA-4 expression on Th17 cells results in increased sensitivity to CTLA-4 coinhibition and resistance to belatacept, Am. J. Transplant, vol.14, pp.607-614, 2014. ,
Costimulation Blockade in Kidney Transplantation: An Update, Transplantation, vol.100, pp.2315-2323, 2016. ,
A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal ,
, Am. J. Transplant, vol.10, pp.535-546, 2010.
Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model, Transplantation, vol.90, pp.1321-1327, 2010. ,
Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner, Am. J. Transplant, vol.11, pp.1599-1609, 2011. ,
Homing of regulatory T cells to human skin is important for the prevention of alloimmune-mediated pathology in an in vivo cellular therapy model, PLoS ONE, vol.7, 2012. ,
Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rgammanull mice display a T-effector memory phenotype, PLoS ONE, vol.7, 2012. ,
Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1, J. Exp. Med, vol.177, pp.165-173, 1993. ,
Deleterious effect of CTLA4-Ig on a Treg-dependent transplant model, Am. J. Transplant, vol.12, pp.846-855, 2012. ,
Inhibitory effects of belatacept on allospecific regulatory T-cell generation in humans, Transplantation, vol.96, pp.689-696, 2013. ,
Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors, Arch. Dermatol, vol.140, pp.1490-1495, 2004. ,
Imiquimod 5% cream induced psoriasis: A case report, summary of the literature and mechanism, Br. J. Dermatol, vol.164, pp.670-672, 2011. ,
Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas, Clin. Exp. Dermatol, vol.31, pp.140-141, 2006. ,
Aldara(R)-induced skin inflammation: Studies of patients with psoriasis, Br. J. Dermatol, vol.172, pp.345-353, 2015. ,
Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis, J. Immunol, vol.182, pp.5836-5845, 2009. ,
Rorgammat+ innate lymphocytes and gammadelta T cells initiate psoriasiform plaque formation in mice, J. Clin. Investig, vol.122, pp.2252-2256, 2012. ,
Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation, Immunity, vol.35, pp.596-610, 2011. ,
Selective CD28 antagonist prevents induced skin inflammation in non-human primates, Exp. Dermatol, vol.25, pp.233-234, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-02150253
Immunopathogenesis of delayed-type hypersensitivity, Microsc. Res. Tech, vol.53, pp.241-245, 2001. ,
Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3(+))-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates, Clin. Exp. Immunol, vol.164, pp.265-274, 2011. ,
Selective CD28 Antagonist Blunts Memory Immune Responses and Promotes Long-Term Control of Skin Inflammation in Nonhuman Primates, J. Immunol, vol.196, pp.274-283, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-02150299
EAE: Imperfect but useful models of multiple sclerosis, Trends Mol. Med, vol.17, pp.119-125, 2011. ,
Selective blockade of CD28-mediated T cell costimulation protects rhesus monkeys against acute fatal experimental autoimmune encephalomyelitis, J. Immunol, vol.194, pp.1454-1466, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-02148517
Antagonizing the alpha4beta1 integrin, but not alpha4beta7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis, J. Immunol, vol.190, pp.1961-1973, 2013. ,
Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis, Clin. Exp. Immunol, vol.183, pp.405-418, 2016. ,
, Immunity, vol.34, 2011.
Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in, Transplantation: Impact on Memory T Cells? Front. Immunol, vol.6, p.411, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-02148498
Immunologic mechanisms of uveitis. New targets for immunomodulation, Arch. Ophthalmol, vol.115, pp.520-525, 1997. ,
Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study, Ophthalmology, vol.111, pp.491-500, 2004. ,
Biotherapies in Behcet's disease, Autoimmun. Rev, vol.13, pp.762-769, 2014. ,
Diagnosis and classification of reactive arthritis, Autoimmun. Rev, vol.13, pp.546-549, 2014. ,
Sarcoidosis and uveitis, Autoimmun. Rev, vol.13, pp.840-849, 2014. ,
Choroidal bulging in patients with Vogt-Koyanagi-Harada disease in the non-acute uveitic stage, J. Ophthalmic Inflamm ,
Immunopharmacotherapy of non-infectious uveitis: Where do we stand? Expert Opin, Biol. Ther, vol.14, pp.1719-1722, 2014. ,
Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial, Proc. Natl. Acad. Sci, vol.96, pp.7462-7466, 1999. ,
Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease, Arthritis Rheum, vol.45, pp.252-257, 2001. ,
Immunotherapeutic strategies in autoimmune uveitis, Autoimmun. Rev, vol.13, pp.909-916, 2014. ,
A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens, J. Immunol, vol.140, pp.1490-1495, 1988. ,
Establishment and characterization of a murine CD4+ T cell line and clone that induce experimental autoimmune uveoretinitis in B10.A mice, J. Immunol, vol.156, pp.1654-1660, 1996. ,
Autoimmune uveitis elicited with antigen-pulsed dendritic cells has a distinct clinical signature and is driven by unique effector mechanisms: Initial encounter with autoantigen defines disease phenotype, J. Immunol, vol.178, pp.5578-5587, 2007. ,
Either a Th17 or a Th1 effector response can drive autoimmunity: Conditions of disease induction affect dominant effector category, J. Exp. Med, vol.205, pp.799-810, 2008. ,
Novel CD28 antagonist mPEG PV1-Fab' mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-gamma production, PLoS ONE, vol.12, 2017. ,
Blockade of costimulation through B7/CD28 inhibits experimental autoimmune uveoretinitis, but does not induce long-term tolerance, J. Immunol, vol.165, pp.5041-5047, 2000. ,
Co-stimulatory molecules as targets for treatment of lupus, Clin. Immunol, vol.148, pp.369-375, 2013. ,
Treatment of murine lupus with CTLA4Ig, Science, vol.265, pp.1225-1227, 1994. ,
Efficacy and safety of abatacept in lupus nephritis: A twelve-month, randomized, double-blind study, Arthritis Rheum, vol.66, pp.379-389, 2014. ,
The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial, Arthritis Rheum, vol.62, pp.3077-3087, 2010. ,
Prevention of lupus nephritis development in NZB/NZW mice by selective blockade of CD28, Eur. J. Immunol, vol.47, pp.1368-1376, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-02155317
Increased Foxp3(+) CD4(+) regulatory T cells with intact suppressive activity but altered cellular localization in murine lupus, Am. J. Pathol, vol.173, pp.1682-1692, 2008. ,
Anti-CD28 antibody-induced kidney allograft tolerance related to tryptophan degradation and TCR class II B7 regulatory cells, Am. J. Transplant, vol.5, pp.2339-2348, 2005. ,
Anti-CD28 Antibody and Belatacept Exert Differential Effects on Mechanisms of Renal Allograft Rejection, J. Am. Soc. Nephrol, vol.27, pp.3577-3588, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-02150329
Pharmacodynamic, and Safety Profile of a Novel Anti-CD28 Domain Antibody Antagonist in Healthy Subjects, J. Clin. Pharmacol, vol.57, pp.161-172, 2017. ,
, This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, © 2017 by the authors. Licensee MDPI